Skip to main content
ESC Heart Failure logoLink to ESC Heart Failure
. 2022 Jun 6;9(4):2764–2765. doi: 10.1002/ehf2.14007

Corrigendum

PMCID: PMC9288789  PMID: 35666046

In the original published version of the paper of Tahara et al. 1 the authors noticed errors in ‘False positives, false negatives, and inconsistencies between 99mTc‐PYP scintigraphy and biopsy findings’ section and Tables 2 and 3 .

Table 2.

Typical false‐positive and false‐negative cases in planar 99mTc‐PYP scintigraphy for the diagnosis of ATTR‐CM

Planar 99mTc‐PYP scintigraphy results Potential causes of false results
False positive
  • Recent myocardial infarction (<4 weeks)

  • Rib fractures and valvular/annular calcifications

  • AL amyloidosis

  • AApoAI, AApoAII, AApoAIV, and Aβ2M

  • Hypertrophic cardiomyopathy

  • Hydroxychloroquine toxicity

  • Cardiac blood pool

  • Intravenous iron injections

False negative
  • Insufficient amount of amyloid deposits

  • Delayed or premature acquisition in 99m Tc‐PYP scintigraphy

  • ATTRv‐CM with a low sensitivity in scintigraphy (Ser77Tyr or Phe64Leu mutation)

  • Initial diagnosis of cardiac pools with myocardial deposits

Table 3.

Potential causes of inconsistencies between planar 99mTc‐PYP scintigraphy and biopsy findings in suspected ATTR‐CM

Planar 99mTc‐PYP scintigraphy Biopsy Potential causes of inconsistencies
Positive Negative
  • Sampling errors in biopsy

  • Errors in scintigraphy imaging time or evaluation

  • Errors in pathological diagnosis

  • Cardiac pools

  • Deposit of proteins other than transthyretin (e.g. AL)

Negative Positive
  • Errors in scintigraphy evaluation

  • Errors in pathological diagnosis

  • Deposit of proteins other than transthyretin (e.g. AL)

  • ATTRv‐CM with a low sensitivity in 99mTc‐PYP scintigraphy (Ser77Tyr or Phe64Leu mutation)

On page 257 of the article, in the ‘False positives, false negatives, and inconsistencies between 99mTc‐PYP scintigraphy and biopsy findings’ section, the cases of ‘rib fractures, valvular/annular calcifications, and recent myocardial infarction’ need to be regarded as false positive instead of false negative. The revised main text should thus read as follows:

‘False‐positive cases in 99mTc‐PYP scintigraphy for ATTR‐CM may include Grade 2 or 3 myocardial uptake; recent myocardial infarction (<4 weeks) 10 ; rib fractures 10 ; valvular/annular calcifications 10 ; AL amyloidosis34,54,69–73; apolipoprotein AI amyloidosis (AApoAI), apolipoprotein AII amyloidosis (AApoAII), apolipoprotein A‐IV amyloidosis (ApoAAIV), or β2‐microglobulin amyloidosis (Aβ2M)10; hypertrophic cardiomyopathy74,75; hydroxychloroquine toxicity76; and cardiac blood pools.54 Case reports on false‐positive myocardial uptake following intravenous iron injections have been published for 99mTc‐DPD and 99mTc‐HMDP scintigraphy.77,78 In contrast, Grade 0 or 1 myocardial uptake, an insufficient amount of amyloid deposits, 79 delayed or premature acquisition in 99m Tc‐PYP scintigraphy, 10 ATTRv‐CM with a low sensitivity for 99mTc‐labelled bone radiotracer scintigraphy (Ser77Tyr or Phe64Leu mutation),10,80 and initial diagnosis of cardiac pools with myocardial deposits81 are examples of possible false‐negative cases (Table 2 ).’

Similarly, the current Table 2 (page 258). ‘Rib fractures and valvular/annular calcifications’ and ‘Recent myocardial infarction (<4 weeks)’ should be removed from false negative causes and combined into false‐positive causes. The revised Table 2 should read as follows:

In addition, the current Table 3 (page 258). The Ser77Tyr mutation should be added to ‘ATTRv‐CM with a low sensitivity in 99mTc‐PYP scintigraphy (Phe64Leu mutation)’ for consistency with Table 2 . The revised Table 3 should thus read as follows:

These errors occurred due to an inadvertent oversight and misinterpretation of source data. This change will not impact any other part of the manuscript including the abstract, and it does not change the data interpretation or conclusions in any way.

Reference

  • 1. Tahara N, Lairez O, Endo J, Okada A, Ueda M, Ishii T, Kitano Y, Lee H‐E, Russo E, Kubo T. 99mTechnetium‐pyrophosphate scintigraphy: A practical guide for early diagnosis of transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022; 9: 251–262. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from ESC Heart Failure are provided here courtesy of Wiley

RESOURCES